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Abstract
Background: Matrix metalloproteinases (MMPs) play a significant role in the fragmentation of myelin basic protein (MBP)
and demyelination leading to autoimmune multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).
The classic MBP isoforms are predominantly expressed in the oligodendrocytes of the CNS. The splice variants of the single
MBP gene (Golli-MBP BG21 and J37) are widely expressed in the neurons and also in the immune cells. The relative
contribution of the individual MMPs to the MBP cleavage is not known.
Methodology/Principal Findings: To elucidate which MMP plays the primary role in cleaving MBP, we determined the
efficiency of MMP-2, MMP-8, MMP-9, MMP-10, MMP-12, MT1-MMP, MT2-MMP, MT3-MMP, MT4-MMP, MT5-MMPand MT6-MMP
in the cleavage of the MBP, BG21 and J37 isoforms in the in vitro cleavage reactions followed by mass-spectroscopy analysis of
the cleavage fragments. As a result, we identified the MMP cleavage sites and the sequence of the resulting fragments. We
determined that MBP, BG21 and J37 are highly sensitive to redundant MMP proteolysis. MT6-MMP (initially called leukolysin),
however, was superior over all of the other MMPs in cleaving the MBP isoforms. Using the mixed lymphocyte culture assay, we
demonstrated that MT6-MMP proteolysis of the MBP isoforms readily generated, with a near quantitative yield, the
immunogenic N-terminal 1–15 MBP peptide. This peptide selectively stimulated the proliferation of the PGPR7.5 T cell clone
isolated from mice with EAE and specific for the 1–15 MBP fragment presented in the MHC H-2
U context.
Conclusions/Significance: In sum, our biochemical observations led us to hypothesize that MT6-MMP, which is activated by
furin and associated with the lipid rafts, plays an important role in MS pathology and that MT6-MMP is a novel and
promising drug target in MS especially when compared with other individual MMPs.
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Introduction
Matrix metalloproteinases (MMPs) comprise a family of 24
enzymes that are expressed by many cell types, especially in
malignancy. Membrane-tethered MMPs (MT-MMPs) are distin-
guished from soluble MMPs by the additional transmembrane and
cytoplasmic domains (MT1-3 MMP and MT5-MMP). In contrast
to these four MT-MMPs, MT4-MMP and MT6-MMP are
attached to the cell membrane via a glycosylphosphatidyl inositol
(GPI) anchor. MMPs cleave the components of the extracellular
matrix as well as multiple growth factors, cytokines and cell-
surface receptors. MMPs are synthesized as latent zymogens. To
become proteolytically active, MMPs require proteolytic removal
of the N-terminal prodomain. MMP-11, MMP-28 and several
MT-MMPs with the motif RXK/RR in their propeptides are
activated by furin [1,2].
Multiple sclerosis (MS) is a disease of the CNS with autoimmune
etiology. Experimental autoimmune encephalomyelitis (EAE), an
inducible disease in laboratory animals, is a widely accepted model
of MS. EAE is induced by autoreactive CD4
+ T cells specific for
myelin antigens. Myelin proteins including proteolipid protein,
myelin oligodendrocyte glycoprotein and especially myelin basic
protein (MBP) are candidate autoantigens in MS. MS is
characterized by multiple regions of focal myelin loss (lesions) and
infiltration of macrophages and lymphocytes in the lesions [3–7].
The demyelination process is manifested as a result of interactions
among encephalitogenic, regulatory and accessory cell populations
and factors, including MMPs produced by these cells. In MS,
MMPs could be responsible for the influx of inflammatory
mononuclear cells into the CNS, contribute to myelin destruction
and affect the integrity of the blood-brain barrier.
Evidence suggests that multiple MMPs cleave MBP and generate
immunogenic peptides and that EAE can be induced by immuni-
zation with MBP or its 1–15, 68–86, 83–99, 84–104 and 87–99
fragments [8–11]. Immunoreactive MBP fragments appear in the
cerebrospinal fluid in MS patients [12,13]. MBP and its Golli splice
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This gene contains three transcription start sites. The first start site is
responsible for the synthesis of the Golli BG21 and J37 isoforms. The
MBPsareexpressedfromthetwodownstreamtranscriptionstartsites
[15]. There are five classic MBP splice products and three Golli splice
products. Of the Golli splice forms only BG21 and J37 contain MBP
sequence. BG21 and J37 are expressed in the CNS and peripheral
nervous system and in immune cells [14,16–18]. The ‘‘classic’’ MBP
is predominantly expressed in the nervous system [15]. The Golli-
MBP isoforms play an incompletely understood role in MS [19,20].
To determine the identity of MMPs which are efficient in the
MBP cleavage and which can contribute to the demyelination
processes, we focused our studies on the individual MMPs which
represent the major MMP groups including gelatinases (MMP-2
and MMP-9), the simple hemopexin MMPs (MMP-8, -10 and -12),
the membrane associated MT-MMPs (MT1-3 and MT5-MMP)
and the GPI-linked MMPs (MT4-MMP and MT6-MMP). We
determined both the efficiency of the individual MMPs in the
cleavage of the MBP isoforms and the precise sequence of the
cleavage sites. We demonstrated that MT6-MMP proteolysis of the
MBP isoforms generated the highly immunogenic N-terminal MBP
peptide which efficiently stimulated the proliferation of the specific
T cell clone isolated from mice with EAE. Based on our data, we
now suspect that by cleaving the MBP and Golli-MBP isoforms
MT6-MMP plays a significant role in the origin of MS in humans.
Results
Isolation of the recombinant constructs
The murine Golli-MBP BG21 and J37 constructs were C-
terminally tagged with a Hisx6 tag (Fig. 1). The constructs were
expressed in E. coli and purified using metal-chelating chroma-
tography. The purified BG21 and J37 samples were readily
recognized by a rabbit polyclonal antibody raised against amino
acids 1–133 of the Golli domain [21] (Fig. 1).
In vitro cleavage of MBP, BG21 and J37 by MMPs
MBP was co-incubated for 1 h at 37uC with the individual
MMPs. The digests were separated by SDS-PAGE (Fig. 2). Where
indicated, the samples included GM6001 (a potent, broad-range
inhibitor of MMPs). MBP was sensitive to proteolysis by many
individual MMPs. MMP-2, MMP-10 and MT6-MMP, however,
were the most efficient in cleaving MBP while MT2-MMP, MT3-
MMP, MT4-MMP and MT5-MMP were the least efficient.
Similarly, MMP-12 and especially MT6-MMP were the most
efficient in the proteolysis of the BG21 and J37 constructs while
MT5-MMP was the least efficient (Fig. 2). We determined that
MT6-MMP was the most efficient among all of the individual
MMPs we tested for cleaving the MBP, BG21 and J37 constructs.
MS analysis of the digest reactions
The MBP, BG21 and J37 constructs were subjected to
proteolysis by the individual MMPs. The mass of the digest
peptides was then determined using MALDI-TOF MS. The
results of a representative MS analysis of MT6-MMP proteolysis of
BG21 are shown in Fig. 3. In our analyses, we tried to identify the
most representative cleavage fragments rather than trying to
determine the identity of each peptide in the samples. To map the
experimental cleavage sites we used a cleavage prediction program
that predicted both the MMP cleavage sites and the size of the
digest fragments. These predictions aided in the precise identifi-
Figure 1. The sequence of the MBP isoforms and the purified BG21 and J37. A, Sequence alignment of murine Golli-MBP BG21 (GenBank
#AAA37721), murine Golli-MBP J37 (GenBank #AAA37720) and human MBP (18.5 kDa; GenBank AAH08749). The immunogenic fragments are
boxed. Identical residues between two proteins are in grey. Identical residues among three proteins are in yellow. B. Constructs and purification of
BG21 and J37. Upper panel - BG21 includes the 1–133 Golli domain and the 1–56 MBP domain. J37 includes the 1–133 Golli domain and the 1–102
and 155–168 fragments of the MBP domain. The constructs were C-terminally tagged with a Hisx6 tag. Bottom panel – purified BG21 and J37. CS,
Coomassie staining. WB, Western blotting with a rabbit polyclonal antibody raised against amino acids 1–133 of the Golli domain [21,49]. C, Sequence
alignment of the human and murine MBP, BG21 and J37 isoforms. Identical residue positions are in yellow. Immunogenic peptide sequences are
boxed.
doi:10.1371/journal.pone.0004952.g001
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PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4952Figure 2. MMPs cleave MBP, BG21 and J37. A, Gel-electrophoresis of the digest samples. MBP, BG21 and J37 were incubated alone for 60 min at
37uC or co-incubated with the individual MMPs at the indicated enzyme-substrate molar ratio. Where indicated, GM6001 was added to the reactions
to block MMPs. B, The MBP isoforms are inefficiently cleaved by certain MMPs. MBP, BG21 and J37 were each co-incubated for 60 min at 37uC with
the indicated MMPs at a 1:100 enzyme-substrate ratio.
doi:10.1371/journal.pone.0004952.g002
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selected partial data are presented in Tables S1, S2, S3. The
cleavage maps of the MBP, BG21 and J37 isoforms are
schematically presented in Fig. 4.
According to our cleavage data, multiple MMPs including MT6-
MMP were capable of readily generating the C-terminal and
especially N-terminal digest peptides of the MBP portion of the
constructs. These peptides were highly similar to the known
immunogenic sequence regions of MBP which were capable of
causing EAE in animal models [9–11]. The peptide that correspond-
ed to the known immunogenic region 68–86 from the central part of
MBP cannot be generated by MMPs because it was cleaved as a
result of MMP proteolysis of the MBP, BG21 and J37 isoforms.
Generally, because of the cleavage preference redundancy among
MMPs, multiple individual MMPs are capable of generating, albeit
with widely varying kinetics, similar cleavage peptide sequences as a
result of the proteolysis of the MBP and Golli-MBP isoforms.
The sequence of the 1–15 region is conserved in the human and
murine MBP and Golli-MBP isoforms and only a two-residue
deletion discriminates the murine and human MBP proteins. As a
result of MMP proteolysis of BG21, only a single known, 1–15,
immunogene could be generated while the cleavage of J37 could
generate both the N- and the C-terminal immunogenic sequences.
Overall, MT6-MMP was the most potent in cleaving the MBP,
BG21 and J37 isoforms and in generating the N-terminal digest
product that corresponded to the known 1–15 immunogenic region
of MBP.
The cleavage of the synthetic peptides by MMPs
To corroborate the MS data and to confirm that MMPs cleave
the SKYQLAT sequence in the MBP isoforms and generate the
immunogenic product that corresponds to the 1–15 sequence of
MBP, we subjected the synthetic peptides ASQKRPSQRHGS-
KYLATAS and ASQKRPSQRSKYLATAS (1 mg each,
,50 mM) to proteolysis by MMP-2, MMP-8, MMP-9 and
MT6-MMP (25 nM each). The first peptide corresponded to the
2–20 sequence of human MBP while the second peptide
corresponded to the 2–18 sequence of murine MBP. The digests
were then analyzed by MALDI-TOF MS. MMP-10 which,
according to our data, could not cleave the SKYQLAT was used
as a control. Consistent with our earlier results, MMP-2, MMP-8,
MMP-9 and MT6-MMP but not MMP-10 cleaved the peptides
and generated the ASQKRPSQRHGSKY and ASQKRPSQR
SKY N-terminal cleavage products of the expected molecular
mass (Table 1).
Activation T cell clone specific to the murine MBP 1–15
fragment
To directly show that MT6-MMP proteolysis generates the
immunogenic 1–15 peptide, we used the digests to stimulate, in the
mixed lymphocyte cultures, the proliferation of the murine T cells
clone which is specific to the 1–15 fragment of MBP. The
PGPR7.5 clone which is specific for the murine MBP 1–15 peptide
presented in the MHC H-2
U context was isolated from EAE mice
[22]. MBP, BG21 and J37 (5 mM each) were cleaved by MT6-
MMP. The irradiated splenocytes from B10.PL mice were co-
incubated with the digests. The PGPR7.5 T cells and H
3-
thymidine were then added to the reactions. The incorporation of
the label into the T cells was measured by liquid scintillation
counting. The digest products were internalized and presented by
the splenocytes and then the presented peptides stimulated the
proliferation of the specific PGPR7.5 T cells. As a control, we used
Figure 3. Representative MALDI-TOF MS spectra of the BG21 sample. BG21 (10 mM) was co-incubated for 60 min at 37uC with MT6-MMP
(0.01 mM). The resulting peptides were analyzed using a Bruker Daltonics Autoflex II MALDI TOF TOF mass spectrometer to determine their molecular
mass. The high and low molecular mass fragments are shown in the top and bottom panels, respectively. The intact and the digested BG21 samples
are in green and red, respectively. The buffer alone, blue line. The numbers in the parentheses show the numbering of the peptide in the BG21
sequence.
doi:10.1371/journal.pone.0004952.g003
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corresponded to the 2–18 sequence of murine MBP and the
stimulatory effect of which we took as 100%. The MT6-MMP
digest of MBP resulted in a 44% level of proliferation of PGPR7.5
T cells compared to the equimolar amount of the
ASQKRPSQRSKYLATAS peptide, thus suggesting a high yield
of the specific immunogenic fragment in the digest (Fig. 5).
A comparable level (34%) of stimulation of the specific
PGPR7.5 T cell clone was observed when the MT6-MMP digest
of BG21 was used in the mixed lymphocyte culture assay. This
lower yield could be explained by the generation of the peptides
(S
136QKRPSQRSKY
146 and Q
137KRPSQRSKY
146), which were
truncated from the N-end when compared to the N-terminal 1–15
ASQKRPSQRHGSKY MBP peptide. Both because of the
cleavage preference of MT6-MMP and the peptide sequence of
J37, overly short peptides (S
136QKRPSQRS
144 and
Q
137KRPSQRS
144) which are truncated from both the N- and
C-ends, will be predominantly generated as a result of the J37
cleavage. It is not surprising that these peptides were not as
efficient in the mixed lymphocyte culture assay as the full-length
1–15 MBP peptide.
Discussion
Several MMP family members contribute to pathology in MS
and EAE [23–27]. The existing data suggest that there are links
among MMP proteolysis of MBP, demyelination and MS [28].
Theses events cause an MBP deficiency, myelin sheath destruction
and axon degeneration leading to MS [24]. When fragmented,
MBP generates several immunogenic peptides which are potent
Figure 4. The cleavage map of MBP, BG21 and J37. The numbers indicate the position of the cleavage sites. The immunogenoic regions are
shown at the bottom of the panel using the MBP residue numbering.
doi:10.1371/journal.pone.0004952.g004
Table 1. Cleavage of the murine (2–18) and human (2–20) MBP peptides by MMPs.
Human MBP 2–20 ASQKRPSQRHGSKYLATAS Murine MBP 2–18 ASQKRPSQRSKYLATAS
Molecular mass, Da Molecular mass, Da
Calculated Measured Calculated Measured
Intact peptide 2073.28 2071.90 1879.09 1877.60
Digest fragment ASQKRPSQRHGSKY ASQKRPSQRSKY
MMP-2 1629.78 1628.54 1435.58 1434.98
MMP-8 1628.56 1441.21
MMP-9 1628.40 1435.02
MT6-MMP 1629.83 1435.92
MMP-10 No cleavage No cleavage
doi:10.1371/journal.pone.0004952.t001
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MS-like diseases and it is induced by immunization with MBP
fragments to induce autoimmune demyelinating EAE in animals.
Several fragments of MBP including 1–15, 68–86, 83–99, 84–104
and 87–99 are known to generate EAE efficiently [9–11]. Multiple
MMP types may be involved in the cleavage of neuronal MBP in
both EAE mice and MS patients [24].
The expression of the classic MBP transcripts is largely
restricted to myelin-forming cells. In turn, the splice variants of
MBP called Golli-MBP BG21 and J37 are expressed in the
thymus, spleen, and lymph nodes [15,32]. In addition to lymphoid
cells, the Golli-MBP isoforms are present in the myeloid lineage
cells, including macrophages, dendritic cells and granulocytes, as
well as in megakaryocytes and erythroblasts. Because of the
presence of the common exons in MBP, BG21 and J37, their
fragmentation can generate similar immunogenic peptides includ-
ing the fragment from the 1–9 and 1–15 immunogenic region and
a source of a dominant T cell clonotype in EAE [33].
Our model in vitro cleavage experiments in which we used
multiple individual MMPs and which were followed by MALDI-
TOF MS analysis of the MBP, BG21 and J37 fragments
demonstrated that multiple individual MMPs including MMP-2,
MMP-8, MMP-9, MMP-10, MMP-12, MT1-MMP and MT6-
MMP were capable of efficiently cleaving the MBP, BG21 and J37
isoforms. The GPI-linked MT6-MMP/MMP-25, however, was
the most efficient in both cleaving these isoforms and generating
the immunogenic 1–15 MBP fragment. The specificity of MT6-
MMP proteolysis of the MBP, BG21 and J37 proteins and the
extremely high, near quantitative, yield of the 1–15 fragment was
confirmed by using the mixed lymphocyte cultures in which
proliferation of the PGPR7.5 T cell clone specific for the 1–15
fragment of MBP presented in the MHC H-2
U context was
stimulated by the digest samples and the level of stimulation was
compared to that generated by the equimolar amount of the
synthetic 1–15 ASQKRPSQRSKYLATAS MBP peptide. Con-
sistent with our results, MT1-MMP and MT6-MMP are
upregulated in the spinal cord of SJL mice with severe EAE
induced by adoptive transfer of myelin basic protein-reactive T
cells while the other four MT-MMPs are down-regulated [34].
MT6-MMP is a distant relative of MT1-MMP, an archetype
membrane-tethered MMP. MT6-MMP is an insufficiently stud-
ied, GPI-linked, lipid raft-associated cell surface MMP with an
incompletely understood regulation and function [35–38]. Among
MMPs, the expression of MT6-MMP (initially called leukolysin) is
most selectively linked to the leukocyte lineage cells [39–41] and
up-regulated in certain cancer types including brain tumors
[37,41]. It should be noted that BG21 relocates to the caveolae-
enriched lipid rafts upon phorbol ester stimulation of T cells
leading to the activation of protein kinase C [42]. The presence of
both BG21 and GPI-linked MT6-MMP in the lipid rafts increases
the opportunity for the selective MT6-MMP proteolysis of the
Golli proteins in the stimulated immune system cells.
Overall, our results on the redundant role of multiple individual
MMPs in the destruction of MBP correlate well with the
observations by many authors who have suggested the important
role MMPs play in the cleavage of MBP, leading to the generation
of immunogenic fragments and demyelination in both EAE and
human MS [15,24,43,44]. Our results support and extend these
earlier observations. Our combined biochemical observations have
led us to hypothesize that MT6-MMP plays an especially
significant role in the proteolytic pathway to MS and, therefore,
may represent a novel and promising drug target. We now believe
that the proteolytic pathway leading to MS involves the MT6-
MMP proteolysis of the Golli-MBP isoforms in the immune system
cells followed by the stimulation of the specific autoimmune T cell
clones which then home through the disrupted blood-brain barrier
to the brain and recognize neuronal MBP. In the brain, these
autoimmune T cells can cause inflammation leading to further
upregulation of the activity of multiple MMPs and the massive
cleavage of MBP in the brain resulting in demyelination and MS.
Our current on-going experiments support this hypothesis
(manuscript in preparation).
Materials and Methods
Reagents
All reagents unless otherwise indicated were from Sigma. A
hydroxamate inhibitor of MMPs (GM6001) was from Chemicon.
A hydroxamate inhibitor of MMPs AG3340 was kindly provided
by Dr. Peter Baciu (Allergan, Irvine, CA). MBP (18.5 kDa isoform,
GenBank #AAH08749) was purchased from Biodesign. The
CD
4+ T cells specific to murine MBP 1–15 fragment were kindly
provided by Dr. Vipin Kumar (Torrey Pines Institute for
Molecular Studies, San Diego, CA). The ASQKRPSQRHGS-
KYLATAS and ASQKRPSQRSKYLATAS peptides, which
corresponded to the sequence 2–20 of human MBP and 135–
153 of BG21 and J37, and to the sequence 2–18 of murine MBP
and 135–151 of BG21 and J37, respectively, were synthesized by
GenScript.
Expression and purification of Golli-MBP BG21 and J37
The plasmids pET22B-BG21 and pET22B-J37 expressing
Golli-MBP BG21 (GenBank #AAA37721) and Golli-MBP J37
(GenBank #AAA37720) were constructed earlier [42]. The J37
and BG21 constructs were C-terminally tagged with a 6xHis tag.
E. coli BL21 (DE3)-Codon Plus-RIPL cells (Stratagene) were
transformed using the plasmids. The expression of the J37 and
BG21 constructs was induced by 1 mM isopropyl b-D-thiogalacto-
side for 6 h. The BG21 and J37 proteins were isolated from the
soluble fraction of E. coli cells on a HiTrap Co
2+-chelating
Sepharose FastFlow column (GE Healthcare). The constructs were
Figure 5. MT6-MMP proteolysis of MBP generates highly
specific immunogenic peptides which efficiently stimulate
the proliferation of the specific T cell clone. MBP, BG21 and J37
(5 mM each) were cleaved by MT6-MMP (an enzyme-substrate ratio of
1:100). The irradiated splenocytes from B10.PL mice were co-incubated
with the digest reactions. The CD4
+ T cells (clone PGPR7.5) specific for
the murine 1–15 MBP peptide presented in the MHC H-2
U context were
then added to the reactions. H
3-thymidine was then added to the cells.
The incorporation of the label into the T cells was measured by liquid
scintillation counting. MBP alone, BG21 alone and J37 alone - intact
MBP, BG21 and J37 (5 mM each) were added to the cells. Cells alone, no
peptide. The 1–15 ASQKRPSQRSKYLATAS MBP peptide (5 mM) was used
as a control (=100%). The numbers show the percentage relative to the
peptide control.
doi:10.1371/journal.pone.0004952.g005
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concentrated using a 5 kDa-cutoff concentrator (Millipore) and
dialyzed against 10 mM Tris-HCl, pH 8.0, containing 200 mM
NaCl.
In vitro cleavage reactions and mass-spectrometry
analysis
The ASQKRPSQRHGSKYLATAS and ASQKRPSQRSKY-
LATAS peptides (1 mg; ,50 mM each) were co-incubated with the
individual MMPs (25 nM) for 1 h at 37uC in 50 mM HEPES,
pH 6.8, supplemented with 10 mM CaCl2, 0.5 mM MgCl2 and
50 mM ZnCl2. The mass of the digested peptides was determined
by Matrix-Assisted Laser Desorption Ionization-Time of Flight
Mass Spectrometry (MALDI-TOF MS) using an Autoflex II
MALDI TOF/TOF instrument (Bruker Daltonics). For mass
spectrometric analysis, equal volumes of a sample and of an a-
cyano-4-hydroxy-cinnamic acid (20 mg/ml) in 50% acetonitrile-
0.1% trifluoroacetic acid solution were co-crystallized directly on
the MALDI target plate and allowed to dry for 5 min.
MBP (4 mg; ,10 mM) and Golli-MBP BG21 (4 mg, ,10 mM)
and J37 (5.5 mg, ,10 mM) were co-incubated with the individual
MMPs (1–100 nM) in 50 mM HEPES, pH 6.8, supplemented
with 10 mM CaCl2 and 50 mM ZnCl2, for 1 h at 37uC. Where
indicated, GM6001 (2.5 mM) was added to the reactions to inhibit
MMPs. The cleavage was stopped using a 5xSDS sample buffer.
The digest samples were analyzed by SDS-PAGE and by MALDI-
TOF MS. For mass spectrometry analysis, the reactions were
cooled on ice and equal volumes of a sample and of a sinapic acid
(20 mg/ml) in 50% acetonitrile-0.1% trifluoroacetic acid solution
were co-crystallized directly on the MALDI target plate and
allowed to dry for 5 min. Mass spectra were processed with
FlexAnalysis 2.4. The singly charged cleavage products, which
were observed only in the cleavage reactions but not in the
controls, were recorded and processed further.
Expression and purification of MMPs
The individual catalytic domains of MMP-10 and MMP-12
were purchased from Biomol. The individual catalytic domains of
MMP-2, -8, -9, and MT1-MMP, MT2-MMP, MT3-MMP, MT4-
MMP, MT5-MMP and MT6-MMP were expressed in E. coli,
purified from the inclusion bodies using metal-chelating chroma-
tography and refolded to restore their native conformation [45].
The refolded MMPs were used immediately in activity assays. The
concentration of the catalytically active MMPs was measured
using a fluorescent assay by titration against a standard AG3340
solution of known concentration. (7-methoxycoumarin-4-yl)Ace-
tyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-diaminopropio-
nyl)-Ala-Arg-NH2 (Bachem) was used as a fluorescent substrate.
The steady-state rate of the substrate cleavage by MMP was
plotted as a function of inhibitor concentration and fitted with the
equation V=SA(E020.5{(E0+I+Ki)2[(E0+I+Ki)
224E0I]
0.5}), where
V is the steady-state rate of substrate hydrolysis, SA is specific activity
(rate per unit of enzyme concentration), E0is enzyme concentration. I
is inhibitor concentration, and Ki is the dissociation constant of the
enzyme-inhibitor complex [46].
Prediction and ranking of the cleavage sites
To predict the cleavage sites for the individual MMPs in the
sequence of MBP and Golli-MPBs BG21 and J37 we used a
specialized computer program we had developed. The program
determines the contribution of each amino acid residue at each of the
P3-P29 positions to the efficiency of the protein proteolysis by a
proteinase and assigns a numerical score to every peptide bond in the
protein sequence. The score is based on the Positional Weight Matrix
(PWM) approach we developed for the individual MMPs using the
high volume data from the substrate phage library cleavage. The
elements of the PWM define the probability of the presence of each
amino acid type at the P3 to P29 sub-site position of the substrate
relative to the cleavage-resistant substrates. The PWM score is a sum
of the log2 elements (log-odds) of the P3 to P29 positions (eq.1–2).
Score~
X P2’
j~P3
Sj iAA ðÞ ð 1Þ
Sj iAA ðÞ ~
log2 PWM iAA,j ðÞ ðÞ
offset, if PWM iAA,j ðÞ ~0
 
ð2Þ
where j is the j-th position near the cleavage site and iAA is the amino
acid type. The offset and thresholdvaluesarespecificforeachMMPand
they were determined using the 10-fold cross-validation test. A
peptide bond is considered to be cleavable if the score value exceeds
the threshold value. The offset is the log2 value of the score when the
PWM element equals to zero. The data were filtered using the Jnet
secondary structure prediction software [47] and the Disopred2
disordered region prediction software [48]. Only those potential
cleavage sites which were predicted by both programs to be at the
high, 5–9, confidence levels to be localized in the unstructured and
disordered regions were considered further.
Stimulation of the murine T cell clone PGPR7.5 specific to
the 1–15 MBP fragment
Prior to the assay, the E. coli-derived BG21 and J37 samples
were purified using an Affinity Pak Detoxi-Gel kit (Thermo
Scientific) to remove LPS. MBP, Golli-MBP BG21 and Golli-MBP
J37 (5 mM each) were cleaved for 1 h at 37uC by MT6-MMP
(0.05 mM; an enzyme-substrate ratio of 1:100). The irradiated
splenocytes from B10.PL mice (1610
6) were co-incubated for 1 h
with the digest reactions. As controls, intact MBP and the murine
2–18 MBP/135–151 Golli-MBP peptide ASQKRPSQRSKYLA-
TAS (5 mM each) were used. The CD4
+ T cells (5610
5; clone
PGPR7.5) specific for murine 1–15 peptide presented in the MHC
H-2
U context were then added to the reactions for 72 h. H
3-
thymidine (1 m Ci) was then added to the cells for 14 h. The
incorporation of the label into the T cells was measured by liquid
scintillation counting.
Supporting Information
Table S1 MMP proteolysis of MBP and a MALDI-TOF MS
analysis of the digest fragments. The arrows indicate the positions of
the scissile bonds. The numbering starts from the N-terminal
methionine.
Found at: doi:10.1371/journal.pone.0004952.s001 (0.10 MB
DOC)
Table S2 MMP proteolysis of Golli-MBP BG21 and a MALDI-
TOF MS analysis of the digest fragments. The arrows indicate the
positions of the scissile bonds. The numbering starts from the N-
terminal methionine.
Found at: doi:10.1371/journal.pone.0004952.s002 (0.13 MB
DOC)
Table S3 MMP proteolysis of Golli-MBP J37 and a MALDI-
TOF MS analysis of the digest fragments. The arrows indicate the
positions of the scissile bonds. The numbering starts from the N-
terminal methionine.
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